Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
Allergan bolsters aesthetics pipeline with Exicure hair loss dealAllergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and Share XAllergan bolsters aesthetics pipeline with Exicure hair loss dealhttps://pharmaphorum.com/news/allergan-bolsters-aesthetics-unit-with-exicure-hair-loss-deal/
Allergan pays $750m to avoid Alzheimer’s drug lawsuitAllergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of Share XAllergan pays $750m to avoid Alzheimer’s drug lawsuithttps://pharmaphorum.com/news/allergan-pays-750m-to-avoid-alzheimers-drug-lawsuit/
Allergan gets FDA okay for paediatric Botox useThe FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the Share XAllergan gets FDA okay for paediatric Botox usehttps://pharmaphorum.com/news/allergan-gets-fda-okay-for-paediatric-botox-use/
Unions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerUS antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion Share XUnions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerhttps://pharmaphorum.com/news/unions-call-on-us-antitrust-regulators-to-block-63-billion-abbviegan-merger/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Allergan says it will shed two drugs as AbbVie takeover loomsAllergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead Share XAllergan says it will shed two drugs as AbbVie takeover loomshttps://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/
Allergan pulls breast implants after link to rare cancerAllergan has followed through on an FDA request to carry out a worldwide recall of textured breast implant Share XAllergan pulls breast implants after link to rare cancerhttps://pharmaphorum.com/news/allergan-pulls-breast-implants-after-link-to-rare-cancer/
AbbVie ducks bolt-on trend and agrees Allergan mega-mergerUS drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew Share XAbbVie ducks bolt-on trend and agrees Allergan mega-mergerhttps://pharmaphorum.com/news/abbvie-ducks-bolt-on-trend-and-agrees-allergan-mega-merger/